Current Protein & Peptide Science
Toggle navigation
Menu
Home
FOR AUTHORS
ARTICLES
SUBSCRIBERS&CORPORATES
FOR REVIEWERS
CONTENTS&ABSTRACTS
CONTACT US
Thursday, April 13, 2017
Free Trial Request
12:02 AM
bentham
No comments
Free Trial Request
Email This
BlogThis!
Share to X
Share to Facebook
Related Posts:
Free Trial Request
Free Trial request …
Read More
Free Online Issue of Current Protein & Peptide Science
Free Online Issue of Current Protein & Peptide Science …
Read More
Highlighted Article: Enantioselective Phytotoxicity and the Relative Mechanism of Current Chiral Herbicides
Highlighted Article: Enantioselective Phytotoxicity and the Relative Mechanism of Current Chiral Herbicides …
Read More
The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Author(s): Minying Cai and Victor J. HrubyPages 488-496 (9) Abstract: The melanocortin receptor system consists of five closely related G-protein coupled receptors (MC1R, MC2R, MC3R, MC4R and MC5R). These receptors ar…
Read More
Call For Paper
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of Current Protein & Peptide Science …
Read More
← Newer Post
Home
Older Post →
0 comments:
Post a Comment
Subscribe to:
Post Comments (Atom)
Open Access Articles
The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Thioredoxin Reductase and its Inhibitors
Blog Archive
►
2018
(3)
►
April
(1)
►
February
(1)
►
January
(1)
▼
2017
(41)
►
December
(1)
►
November
(1)
►
October
(4)
►
September
(2)
►
August
(4)
►
July
(4)
►
June
(3)
►
May
(5)
▼
April
(3)
Call For Paper
Free Trial Request
Open Access Article: Disintegrins from Snake Venom...
►
March
(6)
►
February
(2)
►
January
(6)
►
2016
(24)
►
December
(6)
►
November
(4)
►
October
(8)
►
August
(1)
►
June
(5)
12:02 AM
0 comments:
Post a Comment